The new millennium opens an era of extraordinary, promise for sickle cell disease patients in the United States. Effective therapies are now available and longer, productive lives with proven cost savings are possible; novel treatments are undergoing clinical trials; understanding the biology, of the disease is being energized by new insights into vascular biology and the human genome. To meet the challenges and seize the opportunities of sickle cell disease research, the Boston Sickle Cell Center will carry out novel therapeutic trials in sickle cell anemia and HbSC disease focusing on the induction of HbF and prevention of dehydration of sickle erythrocytes. More basic studies will focus on erythrocyte biology and include studies of cation transport and the effect of hypoxlia and oxidation on the Gardos channel of both normal and sickle erythrocytes and adhesive properties of sickle erythrocytes. The role of nitric oxide in the pathobiology of sickle cell disease will be examined by defining the role of NO in the pulmonary and vascular responses in a sickle cell transgenic mouse. We will also: build a clinical core that will form a foundation for therapeutic trials; provide education and counseling for patients and medical professionals; provide a national resource for hemoglobinopathy testing. All components of the Boston Comprehensive Sickle Cell Center will be melded into a cohesive unit to increase its effectiveness beyond the sum of its components and encourage interactions with other local and national sickle cell centers.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Evans, Gregory
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston Medical Center
United States
Zip Code
Maron, Bradley A; Oldham, William M; Chan, Stephen Y et al. (2014) Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation 130:168-79
Cottrill, Katherine A; Chan, Stephen Y; Loscalzo, Joseph (2014) Hypoxamirs and mitochondrial metabolism. Antioxid Redox Signal 21:1189-201
Loscalzo, Joseph; Handy, Diane E (2014) Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). Pulm Circ 4:169-74
Zhao, Yuzheng; Yang, Yi; Loscalzo, Joseph (2014) Real-time assessment of the metabolic profile of living cells with genetically encoded NADH sensors. Methods Enzymol 542:349-67
Barroso, Madalena; Florindo, Cristina; Kalwa, Hermann et al. (2014) Inhibition of cellular methyltransferases promotes endothelial cell activation by suppressing glutathione peroxidase 1 protein expression. J Biol Chem 289:15350-62
Maron, Bradley A; Waxman, Aaron B; Opotowsky, Alexander R et al. (2013) Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 112:720-5
Handy, Diane E; Loscalzo, Joseph; Leopold, Jane A (2013) Systems analysis of oxidant stress in the vasculature. IUBMB Life 65:911-20
Nallamshetty, Shriram; Chan, Stephen Y; Loscalzo, Joseph (2013) Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med 64:20-30
Silverman, E K; Loscalzo, J (2013) Developing new drug treatments in the era of network medicine. Clin Pharmacol Ther 93:26-8
Kao, Derrick D; Oldebeken, Scott R; Rai, Anjali et al. (2013) Tumor necrosis factor-?-mediated suppression of dual-specificity phosphatase 4: crosstalk between NF?B and MAPK regulates endothelial cell survival. Mol Cell Biochem 382:153-62

Showing the most recent 10 out of 82 publications